Alternatively, for patients with a PD-L1 tumor proportion score (TPS) of ≥ 1%, the recommended treatment is either nivolumab plus platinum and fluoropyrimidine or nivolumab plus ipilimumab. Here, CD274 is linked to neoplasm.